Frontline Use of Erythroid Maturating Agent (EMA): Luspatercept

home / case-based-peer-perspectives / frontline-use-of-erythroid-maturating-agent-ema-luspatercept

Chris Benton, MD, presents a patient case and provides clinical insights on the use of luspatercept, an erythroid maturating agent, in patients with lower-risk myelodysplastic syndromes.

1 KOL is featured in this series.

EP. 1: First-Line Treatment Selection in Lower-Risk MDS

Chris Benton, MD
June 28th 2024

Chris Benton, MD, provides an overview of first-line treatment options for patients with lower-risk myelodysplastic syndromes (LR-MDS).

Watch